CD40LG and COVID-19: A single-center retrospective study showed that (Liu X. et al., 2020) COVID-19 patients with severe/critical had a higher risk of clinical adverse events when the IgM titer was higher than 50 AU/ml, and a lower IgM titer in severe/critical patients may indicate a better prognosis.